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The genomes of three closely related bordetellae are currently being sequenced, thus providing an oppor-
tunity for comparative genomic approaches driven by an understanding of the comparative biology of these
three bacteria. Although the other strains being sequenced are well studied, the strain of Bordetella paraper-
tussis chosen for sequencing is a recent human clinical isolate (strain 12822) that has yet to be characterized
in detail. This investigation reports the first phenotypic characterization of this strain, which will likely become
the prototype for this species in comparison with the prototype strains of B. pertussis (Tohama I), B. bronchi-
septica (RB50), and other isolates of B. parapertussis. Multiple in vitro and in vivo assays distinguished each
species. B. parapertussis was more similar to B. bronchiseptica than to B. pertussis in many assays, including in
BvgS signaling characteristics, presence of urease activity, regulation of urease expression by BvgAS, virulence
in the respiratory tracts of immunocompromised mice, induction of anti-Bordetella antibodies, and serum
antimicrobial resistance. In other assays, B. parapertussis was distinct from all other species (in pigment
production) or more similar to B. pertussis (by lack of motility and cytotoxicity to a macrophage-like cell line).
These results begin to provide phenotypes that can be related to genetic differences identified in the genomic
sequences of bordetellae.
Bordetella pertussis, B. bronchiseptica, and B. parapertussis
are gram-negative bacteria so closely related that they are
considered subspecies (20, 26) and were recently described as
the “classical” Bordetella (for a review, see reference 12). B.
pertussis infects only humans, causing the acute respiratory
disease known as whooping cough (pertussis) (5). B. bronchi-
septica infects a wide variety of mammals and occasionally
humans (14, 36). Although it frequently causes chronic asymp-
tomatic infections (6), B. bronchiseptica can cause kennel
cough in dogs, atrophic rhinitis in pigs, snuffles in rabbits, and
bronchopneumonia in guinea pigs (13). B. parapertussis infects
humans, causing a disease that is nearly indistinguishable from
that caused by B. pertussis despite the failure of this organism
to express pertussis toxin (18, 35). A bacterium also identified
as B. parapertussis was isolated from the respiratory tracts of
healthy sheep and sheep with chronic nonprogressive pneumo-
nia (8, 28). Molecular phylogenetic analyses (28, 29, 33, 34, 38)
found isolates from sheep (B. parapertussisov) to be distinct
from those isolated from humans (B. parapertussishu) and B.
bronchiseptica. These phylogenetic analyses suggest that B.
parapertussishu, B. parapertussisov, and B. pertussis have each
evolved independently from B. bronchiseptica (12, 33, 34). The
host range, disease pathology, and ability to cause chronic or
acute infection differ among the bordetellae (12), suggesting
that informative phenotypes underlying these differences re-
main to be characterized.
The genomes of the RB50 strain of B. bronchiseptica (6), the
Tohama I (5, 36) strain of B. pertussis (19), and the 12822 strain
of B. parapertussishu are currently being sequenced by the
Sanger Centre (http://www.sanger.ac.uk/Projects/Microbes).
The 12822 strain of B. parapertussishu was isolated in Erlangen,
Germany, during a prospective surveillance program (18). This
strain was isolated from a nasopharyngeal swab taken from a
16-month-old boy by his pediatrician in July 1993. The boy had
been coughing for 1 week, had no fever, and had not received
any pertussis immunization. The cough was paroxysmal, and
whooping was present, but there was no posttussive vomiting.
His white blood cell count was normal (9,400 leukocytes/l and
a 59% lymphocyte component), and he recovered completely
after coughing for a total of 5 weeks, as is typical of B. para-
pertussis infections. The disease caused by strain 12822 in this
boy is characteristic of that caused by B. parapertussis in hu-
mans (18). This characteristic, along with the apparent high
genetic homogeneity of isolates of B. parapertussishu (12, 38),
makes strain 12822 a good representative strain for genomic
and phenotypic investigations.
Phenotypes for the RB50 and Tohama I strains are well
characterized, but the phenotypic characteristics for strain
12822 are not known. This investigation identifies the pheno-
typic similarities and differences between the 12822 strain of B.
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parapertussishu being sequenced and closely related strains of
bordetellae under the conditions of in vitro culture, including
phenotypic modulation, motility, pigment production, urease
activity, serum antimicrobial killing, and macrophage toxicity,
and in vivo respiratory infection of immunocompetent mice
and immunodeficient mice. The results of this investigation
indicate that B. parapertussishu shares more phenotypic simi-
larities with B. bronchiseptica than it does with B. parapertus-
sisov or B. pertussis. They also suggest that, among the classical
species of Bordetella, phenotypic variation in host range, dis-
ease pathology, and process of infection is due to important
differences in the presence and/or expression of only a small
number of bacterial factors involved in host recognition and
persistence.
MATERIALS AND METHODS
Strains and growth conditions. A total of 170 and 10 isolates of B. parapertussis
of human and ovine origin, respectively, were tested in this study. Most of the
human isolates, including the 12822 strain of B. parapertussishu, were obtained
from children with coughing illnesses in various regions of Germany between
1992 and 1997 (Pertussis Study Laboratory at the University Children and Ad-
olescents Hospital, Erlangen, Germany). The others were isolated from humans
with coughing illnesses in Finland (n  10), France (n  2), Italy (n  10), The
Netherlands (n  9), Sweden (n  18), and the United States (n  4). Strains of
B. parapertussisov were isolated from sheep in New Zealand (n  5), such as
Fr107, or Scotland (n 5), such as H1. The Tohama I (strain 536), 18323 (ATCC
9797), GMT1, and CS strains of B. pertussis have been described previously (19,
22, 23). The RB50, RB53, RB54, GP1SN, and WD3 strains of B. bronchiseptica
have been described previously (1, 6, 37).
All bordetellae were grown on Bordet-Gengou (BG) agar (Becton Dickinson
Microbiology Systems) supplemented with 7.5% (for B. bronchiseptica and B.
parapertussis) or 15% (for B. pertussis) defibrinated sheep blood. Motility assays
were performed by stabbing colonies into Luria-Bertani or Stainer-Scholte (SS)
medium containing soft agar (0.25 to 0.35% agar). Pigment production on ty-
rosine agar prepared as previously described (11, 28) and on BG-blood agar was
examined in side-by-side comparisons. Nicotinic acid or MgSO4 was added to the
various media to induce Bvg modulation. Bacteria were incubated at 37°C.
Construction of Bvg-phase-locked strains of B. parapertussis. The bvgS
derivatives of the 12822 strain of B. parapertussishu and the H1 strain of B.
parapertussisov were constructed using allelic exchange in a manner analogous to
construction of the RB54 strain of B. bronchiseptica (6). Briefly, the bvgAS locus
from the GP1 strain of B. bronchiseptica (1) was cloned into allelic exchange
vector pEG25 (22) as a 5.2-kb EcoRI fragment. The 1.4-kb BglII-BclI fragment
was then removed to delete amino acids 541 to 1000 spanning the second
transmembrane domain, the linker, the transmitter, and most of the receiver
domain of BvgS. This plasmid, pUH10, was used to replace the wild-type bvgAS
loci of strains 12822 and H1 with the deletion mutation allele, resulting in the
construction of strains 12822bvgS and H1bvgS, respectively. PCR was used to
confirm the genetic organization of the bvgAS loci in both bvgS strains. Both
bvgS strains formed large, flat, nonhemolytic colonies on BG-blood agar, which
contained 40 mM MgSO4 or 20 mM nicotinic acid.
Assay for urease activity. Strains of bordetellae were grown in Luria-Bertani
or SS broth containing 0 or 40 mM MgSO4 and 0 or 10 mM urea as indicated (see
Table 1). An aliquot of each culture (about 103 CFU) was plated onto BG-blood
agar plates to detect the occurrence of spontaneous Bvg mutants. Experiments
in which Bvg variants were detected were discarded. Bacteria used in the assay
were collected by centrifugation of 500 l of broth culture (optical density, 0.25),
resuspended in 500 l of urease test broth (85.6 mM NaCl, 14.7 mM KH2PO4,
33.3 mM urea, 13.2 M phenol red), and incubated at 37°C for 24 h. The color
change resulting from the increased pH due to the release of ammonia from urea
was detected by measuring the absorbance at 560 nm.
ELISA, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and im-
munoblotting. Titers of anti-Bordetella antibodies in serum samples collected 30
days after infection of mice with strain 12822, Fr107, RB50, or GMT1 were
quantified by enzyme-linked immunosorbent assay (ELISA) as previously de-
scribed (6) using whole cells from cultures of the respective bacterial strains.
Mean titer values were compared by unpaired Student’s t tests. Proteins in
whole-cell extracts solubilized in sample buffer were separated on sodium dode-
cyl sulfate-polyacrylamide electrophoresis gels as described previously (6) and
transferred to Immobilon-P (Millipore) membranes that were incubated with the
respective anti-Bordetella mouse serum (1:2,000 dilution) to make immunoblots.
Antigen-antibody complexes were detected with horseradish peroxidase-conju-
gated anti-mouse immunoglobulin G (Amersham) at a dilution of 1:2,500 and
visualized by an enhanced chemiluminescence technique (Amersham).
Serum microbe killing and cytotoxicity assays. Both serum microbe killing and
cytotoxicity assays were performed as previously described (15). Briefly, serum
was obtained from rabbits that were Bordetella free (naive) or immunized with
heat-killed RB50, Fr107, 12822, or Tohama I. Bacteria (about 1,000 CFU/10 l)
in mid-log phase were mixed with the indicated serum (90 l) or phosphate-
buffered saline (PBS), incubated at 37°C for 1 h, and spread on BG agar for
determination of bacterial survival. Cytotoxicity of bordetellae to the J774 mac-
rophage cell line was determined at a multiplicity of infection of 10. Bacteria and
J774 cells were incubated together at 37°C for 1 h, and the percentage of J774
cells killed was determined using the Cytotox96 kit (Promega). Mean values
derived from both assays were compared by unpaired Student’s t tests.
Experimental animals. C57BL/6 mice were purchased from Charles River
Laboratories. SCID-beige mice (BALB/c genetic background) were from facili-
ties at the University of California at Los Angeles. All mice used were 4- to
6-week-old females. Inoculation of mice was performed as previously described
(15, 17). Briefly, mice lightly sedated with halothane were inoculated with a high
dose (5  104 CFU in 50 l of PBS) of the designated Bordetella strain by
pipetting the inoculum into the tips of the external nares. Groups of three mice
were sacrificed at each time tested after inoculation. Blood was collected from
mice by cardiac puncture. Colonization of the nasal cavity, trachea (1 cm), and
lungs was quantified as previously described (15, 17). Animals were handled
according to institutional guidelines. Colonization values are reported as means
 standard errors (SE) and compared by unpaired Student’s t tests.
RESULTS AND DISCUSSION
Phenotypic modulation. A hallmark of the bordetellae is
phenotypic modulation controlled by the two-component Bvg-
AS sensory transduction system in response to changes in en-
vironmental conditions (3, 21, 25). The response regulator (A)
and sensor (S) components of this system are encoded in the
bvg locus (4). Although Arico` et al. (4) reported the nucleotide
and deduced amino acid sequences for this locus in multiple
bordetellae, the strains sequenced were not the strains whose
genomes are being sequenced by the Sanger Centre. There-
fore, these sequences for the bvgAS components in strains
Tohama I (strain 536), 12822, and RB50 were compared to
each other and that of the 165 strain of B. pertussis reported by
Arico` et al. (4) (accession number M25401 in the EMBL-
GenBank-DDBJ nucleotide sequence data libraries). The
0.63-kb nucleotide sequence for bvgA from strain 165 was iden-
tical to that from Tohama I (strain 536), which was 99% iden-
tical to that from 12822 and 99.4% identical to that from RB50.
This sequence from strain 12822 was 99.7% identical to that
from RB50. The deduced 219-amino-acid sequence for BvgA
was identical for all three species.
The 3.717-kb nucleotide sequence for bvgS from strain 165
was 99.9% identical to that from Tohama I (strain 536), and
both strains of B. pertussis were 95.3% identical to those from
strains 12822 and RB50. This sequence from 12822 was 99.5%
identical to that from RB50. The deduced 1,238-amino-acid
sequence for BvgS from 165 was 99.8% identical to that from
Tohama I (strain 536), and both strains of B. pertussis were
95.2% identical to those from 12822 and RB50. This sequence
from 12822 was 99.5% identical to that from RB50. As re-
ported by Arico` et al. (4), most of the base pair (67%) and
amino acid (68%) differences among the bvgS sequences com-
pared occurred in the predicted periplasmic regions of BvgS.
This region from 165 was identical in amino acid sequence to
that from Tohama I (strain 536), and both strains of B. pertussis
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were 92% identical in amino acid sequence to those from
12822 and RB50. Interestingly, the amino acid sequence for
the periplasmic region of strain 12822 was identical to that of
RB50. These similarities and differences in sequences are con-
sistent with phylogenetic analyses (33, 34, 38), suggesting that
B. parapertussis is more closely related to B. bronchiseptica than
to B. pertussis.
The BvgAS system mediates the transition between virulent
(Bvg), intermediate, and avirulent (Bvg) phases (7, 9).
When grown at 37°C in the absence of chemical modulators
such as nicotinic acid or MgSO4, classical bordetellae are in the
Bvg phase, in which BvgAS activates the expression of viru-
lence factors and represses motility and virulence-repressed
genes. As the temperature is decreased below 37°C or the level
of chemical modulator is increased, conditions become semi-
modulating and classical bordetellae enter the intermediate
(Bvgi) phase, where BvgAS activates factors that are expressed
exclusively in this phase and only a subset of Bvg-phase fac-
tors (9, 31). Further decreases in temperature or increases in
the level of chemical modulator induced bordetellae to enter
the Bvg phase, where BvgAS is inactive and no longer acti-
vates expression of virulence factors nor represses motility and
virulence-repressed genes. Various in vitro phenotypes, such as
colony morphology, motility, pigment production, and urease
activity, are used to distinguish the bordetellae, characterize
the Bvg phase, or both. Therefore, Bvg control of these in vitro
phenotypes for the 12822 strain of B. parapertussishu was de-
termined and compared to those for B. bronchiseptica and B.
pertussis in order to identify phenotypic similarities.
Expression of flagella and motility in soft agar under Bvg-
phase conditions was previously observed for B. bronchiseptica
but not B. pertussis (1, 2). The observed lack of motility by
strains of B. parapertussis has been previously reported (1, 13,
28) and recently reviewed with that known for other bordetel-
lae (12), but conditions for growth of the bacteria prior to and
during the motility assay were not clearly described in any of
these studies. Therefore, the possibility that, like B. bronchi-
septica, B. parapertussis is motile only under modulating Bvg-
phase conditions was examined. Under no conditions were the
isolates of B. parapertussis tested found to be motile (Table 1),
including isolate K1, which was previously reported to be mo-
tile (28). All strains of B. bronchiseptica tested were motile in
the presence of nicotinic acid, MgSO4, or low temperature.
Under no conditions was motility observed in the strains of B.
pertussis (Table 1) tested and the Bvg-phase-locked deriva-
tives (12822bvgS and H1bvgS) of B. parapertussis. Results
presented here show that, like B. pertussis (1, 2) and unlike B.
bronchiseptica, B. parapertussis is not motile, even under Bvg-
phase conditions.
Production of brown pigment on tyrosine agar, which is
attributed to a tyrosinase that converts tyrosine into a melanin-
like pigment (11), is a phenotype expressed by many strains of
B. parapertussis but not by other bordetellae (11, 28). In this
investigation, pigment production on tyrosine agar and BG-
blood agar by all isolates of bordetellae tested was examined
under Bvg- or Bvg-phase conditions. Brown pigment was
produced under all conditions tested by all 170 isolates of B.
parapertussishu, including strain 12822 (Table 1). This pigment
TABLE 1. General in vitro phenotypic differences between B. parapertussishu and closely related strains
Species (origin) Strain
Assay
Motility Pigment
Colony morphologya (nicotinic
acid [mM])
Urease activityb (urea/MgSO4
[mM])
0 2 4 8 0/0 10/0 0/40 10/40
B. parapertussis (human) 12822, 1–169c          
12822bvgS          
B. parapertussis (ovine; Scotland)d H1, C          
J1, G1, H1bvgS          
K1          
B. parapertussis (ovine; New Zealand) Fr107–Fr111          
B. bronchiseptica (rabbit) RB50 (Bvgwt)e          
RB53 (Bvgc)f          
RB54 (Bvg)g          
B. bronchiseptica (guinea pig) GP1SN          
B. pertussis (human) Tohama I          
GMT1          
18323          
CS          
a , small, domed colonies with a 7- to 10-mm hemolytic halo indicative of the Bvg phase; , medium-sized, flat (ovoid) colonies with a 3- to 7-mm hemolytic
halo indicative of a partial transition between phases; , large, flat, no hemolytic halo indicative of the Bvg phase.
b , high urease activity; , very low or no urease activity. The isolates of B. parapertussishu tested for urease activity were 12822, 84099, 1, 11, RN130, 7254, 476,
89796, 11148, 36842, 13645, 133, and A-168.
c 1–169 are the number of isolates of B. parapertussishu tested.
d B. parapertussisov isolates J1, G1, and K1 from Scotland appear to be Bvg mutants.
e Wild-type.
f Constitutive Bvg-phase-locked derivative of RB50.
g Bvg-phase-locked derivative of RB50.
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was also produced by the isolates of B. parapertussisov from
Scotland, except for K1, which was previously reported to not
produce pigment (28). In contrast, none of the other isolates of
B. parapertussisov from New Zealand, B. bronchiseptica, or B.
pertussis that were assessed produced pigment under any con-
dition tested. Pigment production is not regulated by BvgAS in
the bordetellae and appears to be a conserved phenotype in
only B. parapertussishu.
Hemolytic activity and colony morphology on blood agar
have been shown (22) to be accurate indicators of the sensi-
tivity of BvgAS to signal the Bvg to Bvg transition in re-
sponse to decreasing chemical modulator and increasing tem-
perature. However, the BvgS signaling characteristics of B.
parapertussis have not been previously compared to other clas-
sical bordetellae. As previously described (22), the strains of B.
bronchiseptica tested did not vary in sensitivity to nicotinic acid
concentration whereas the strains of B. pertussis tested did vary
in sensitivity to the modulator tested (Table 1). Uniform sen-
sitivity to relatively low concentrations of nicotinic acid was
observed for strain 12822 and the other 169 isolates of B.
parapertussishu tested, suggesting that B. parapertussishu dis-
plays BvgAS signaling characteristics similar to that of B. bron-
chiseptica. Isolates of B. parapertussisov that are not spontane-
ously occurring Bvg-phase variants (isolates J1, G1, and K1)
also display BvgAS signaling characteristics similar to that of B.
bronchiseptica. The periplasmic domain of BvgS was previously
shown to be responsible for differences in signal sensitivity
(22). Most of the variation in bvgS nucleotide sequences and
BvgS amino acid sequences among the three species coincides
with the periplasmic domain (4). Interestingly, both the signal-
ing sensitivity and the amino acid sequence of the periplasmic
domain of BvgS from B. parapertussis are more similar to those
from B. bronchiseptica than to those from B. pertussis.
Urease activity differentiates the urease-negative B. pertussis
strains from the urease-positive B. parapertussis and B. bron-
chiseptica strains. Like that of other strains of B. bronchiseptica
(24), urease activity in the RB50 strain of B. bronchiseptica and
all isolates of B. parapertussishu tested here was very low under
Bvg-phase conditions but high under modulating Bvg-phase
conditions (Table 1). Regulation of urease activity by BvgAS
was demonstrated in the RB50 and 12822 strains, whose bvgS
derivatives produced urease activity after growth under mod-
ulating and nonmodulating conditions, while no urease activity
was detected in a Bvg constitutive derivative of RB50 (RB53)
grown under either growth condition. In contrast, all isolates of
B. parapertussisov tested, including the bvgS derivative of
strain H1, constitutively expressed urease activity under either
growth condition (Table 1). The presence of 10 mM urea in the
growth medium had no influence on urease production by any
of the strains tested. Control of urease expression by BvgAS,
therefore, represents a phenotype shared by B. bronchiseptica
and B. parapertussishu but not by the other bordetellae tested.
Respiratory tract colonization in immunocompetent mice. A
previous study (15) uncovered differences between the abilities
of the RB50 strain of B. bronchiseptica and the Tohama I strain
of B. pertussis to grow in the respiratory tracts of mice. The
12822 strain of B. parapertussishu, however, has not been ana-
lyzed in vivo. Therefore, a high-dose regimen was used to
examine the abilities of strain 12822 and other classical borde-
tellae to colonize the respiratory tracts of C57BL/6 mice (Fig.
1). Five days after inoculation with RB50 or 12822, levels of
colonization in the nasal cavity, trachea, and lungs were similar
(P  0.2) for both strains. These initial levels of colonization
for RB50 and 12822 were greater than (P  0.001) that of the
FIG. 1. Time course for respiratory tract colonization in C57BL/6
mice by the RB50 strain of B. bronchiseptica (Bb), the 12822 strain of
B. parapertussishu (Bpp Human), or the FR107 strain of B. parapertus-
sisov (Bpp Ovine). Mice were inoculated intranasally with a high dose
(50 l of PBS containing 5  104 CFU) of the indicated strains. At the
indicated times after inoculation, three to six mice were sacrificed and
the number of CFU recovered from the nasal cavity, trachea, and lungs
was determined. The broken line indicates the limit of detection or 10
CFU. Points represent means  SE of the log10 transformation of the
CFU recovered from each mouse.
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Fr107 strain of B. parapertussisov in all sites, with the lower
respiratory tract of these mice being poorly colonized by B.
parapertussisov. Similar to previously reported (17) colonization
results for human-adapted strains of B. pertussis (Tohama I)
and B. parapertussis (CN2591), 12822 efficiently colonized the
entire respiratory tracts of immunocompetent mice.
The persistence of these strains varied with the site in the
respiratory tract tested (Fig. 1). Although RB50 persisted in
greater numbers (P 0.01) in the nasal cavity than 12822, both
RB50 and 12822, but not FR107, persisted in the nasal cavity
throughout the experimental period of 103 days. Persistence of
both RB50 and 12822 in the trachea was similar (50 days
after inoculation; P  0.7) and longer (P  0.001) than that of
Fr107 (	30 days after inoculation). Both 12822 and Fr107
were cleared from the lungs faster (31 days after inoculation)
than RB50 (49 days after inoculation). Using BALB/c mice
and a similar inoculation regimen, Harvill et al. (17) observed
clearance of Tohama I and CN2591 by 28 days after inocula-
tion in the nasal cavity and by 21 days after inoculation in the
trachea and lungs whereas RB50 persisted in the nasal cavity
throughout the experimental period of 50 days and was not
cleared from the trachea and lungs until 50 days after inocu-
lation. These results indicate that the ability to persist in the
respiratory tracts of mice is not a common phenotype of B.
pertussis and B. parapertussis, whereas this ability is a pheno-
type common to strains of B. bronchiseptica.
The abilities of additional isolates (11867, 18763, 133, 11148,
36842, 9100436, 11, A-002, A-168, and 1) of B. parapertussishu
to colonize C57BL/6 mice (one mouse per strain) 5 days after
inoculation with a high-dose inoculation regimen were tested
to determine if their colonization ability differed from that for
strain 12822. Colonization (log10 range) of the nasal cavity,
trachea, and lungs by all additional human isolates tested (5.5
to 6.2, 5.0 to 5.9, and 5.3 to 6.4 CFU, respectively) overlapped
with that for 12822 (6.0 to 6.4, 5.8 to 6.2, and 6.4to 6.6 CFU,
respectively), suggesting that all isolates of B. parapertussis
tested behave similarly in mice. This behavior in mice is con-
sistent with the apparent high genetic homogeneity of isolates
of B. parapertussishu (38).
Serum antibody responses. A previous study (15) uncovered
a vigorous antibody response in mice after infection with the
RB50 strain of B. bronchiseptica and little antibody response
after infection with the Tohama I strain of B. pertussis. There-
fore, the antibody response of mice to the 12822 strain of B.
parapertussishu administered by the intranasal route was com-
pared with this response to other classical bordetellae (Fig. 2)
by ELISAs with the respective strain as antigen. Serum sam-
ples from mice 30 days after inoculation with 12822 contained
similarly high titers (P  0.2) of anti-12822 antibodies that
recognized 12822 and RB50 but lower titers (P  0.02) of
antibodies that recognized the Fr107 strain of B. parapertus-
sisov. Serum samples from mice 30 days after inoculation with
RB50 contained similarly high titers (P  0.4) of anti-RB50
antibodies that recognized only RB50 and 12822. In contrast,
anti-Bordetella antibodies could not be detected above back-
ground in serum samples from mice 30 days after inoculation
with the GMT1 strain of B. pertussis, which was consistent with
previous observations (15) of Tohama I. Serum samples from
mice 30 days after inoculation with Fr107 contained interme-
diate titers of anti-Fr107 antibodies that recognized Fr107 but
not GMT1, RB50, or 12822. In addition, serum samples from
mice infected with 12822, Fr107, or RB50 did not recognize
GMT1 above background (Fig. 2). Western blots used to visu-
alize the repertoire of Bordetella antigens mimicked the trends
observed by ELISA (data not shown). These results demon-
strate that induction of a strong antibody response during
colonization of the mouse respiratory tract is shared by B.
bronchiseptica and B. parapertussishu but greatly diminished in
or absent from B. pertussis and B. parapertussisov.
Serum antimicrobial resistance. Previous studies (15, 17)
found the RB50 strain of B. bronchiseptica, but not the Tohama
I strain of B. pertussis, to be resistant to the innate antimicro-
bial activities of naive serum. Therefore, the resistance of the
12822 strain of B. parapertussishu in serum was compared with
that to other bordetellae (Fig. 3). The high levels of resistance
of 12822 and Fr107 were similar (P  0.4) to that of RB50 in
naive serum. The Tohama I strain of B. pertussis was killed
(95%) by naive serum. None of the bordetellae tested were
resistant to immune serum. These results suggest that, unlike
B. pertussis, both B. bronchiseptica and B. parapertussis have the
phenotypic ability to survive the host’s innate antimicrobial
agents present in blood and lymph fluids.
Virulence in immunodeficient mice. SCID-beige mice, which
are deficient in B cells, T cells, and natural killer cells (10, 30),
were used to compare the ability of the 12822 strain of B.
parapertussishu to overcome innate immunity with that of other
classical bordetellae (Fig. 4). These mice, inoculated with a
high dose of either strain of B. pertussis tested (Tohama I or
GMT1) or the Fr107 strain of B. parapertussisov, showed no
signs of illness throughout the experimental period of 103 days.
In contrast, all SCID-beige mice inoculated with 12822 or the
FIG. 2. Comparison of anti-Bordetella antibody titers in serum sam-
ples collected 30 days after intranasal challenge or infection of mice
with a high dose (50 l of PBS containing 5  104 CFU) of the RB50
strain of B. bronchiseptica, the 12822 strain of B. parapertussishu, the
FR107 strain of B. parapertussisov, or the GMT1 strain of B. pertussis.
Whole cells of the indicated strain were used as the antigen in each
ELISA. The secondary antibody used detected the immunoglobulin of
all isotypes. Bars represent means  SE (n  5) of the log10 transfor-
mation of the immunoglobulin titer detected. The broken line indi-
cates the limit of detection.
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RB50 strain of B. bronchiseptica succumbed to lethal infection
by 24 or 50 days after inoculation, respectively. All strains
tested were recovered from the lungs of mice that survived to
the end of the experimental period, indicating that they shared
the ability to persist in the lower respiratory tract. The obser-
vation that B. parapertussishu was highly virulent in these mice
indicates that the B-cell and T-cell components of adaptive
immunity are required to limit infection by B. parapertussishu,
as previously shown with B. bronchiseptica (15, 17). Immune
mechanisms still active in these mice are able to control B.
parapertussisov, as previously shown with B. pertussis (15, 17).
The virulence of B. bronchiseptica in SCID-beige mice was
previously shown to require expression of adenylate cyclase
toxin (16). Since all of the bordetellae tested here express this
toxin, there is at least one other factor unique to B. bronchi-
septica and B. parapertussishu that is also required for virulence
in these immunodeficient mice. Interestingly, B. parapertus-
sishu, B. parapertussisov, and B. bronchiseptica are highly resis-
tant in vitro to the antimicrobial components in naive serum,
whereas B. pertussis was killed (Fig. 3). Lipopolysaccharides
(LPS) are known to influence serum antimicrobial resistance in
other bacteria, and the LPS structures vary among bordetellae
(12, 27). In addition, the LPS structures of B. bronchiseptica
and B. pertussis correlate with their respective serum antimi-
crobial resistance phenotypes (32). The presence of the mem-
brane distal polysaccharide domains on the LPS of B. bronchi-
septica, B. pertussis, and B. parapertussishu is essential for the
expression of full virulence in immunocompetent (BALB/c)
and immunodeficient (SCID-beige) mice (17). Furthermore,
the presence of the O-antigen-like repeat in the distal polysac-
charide domain of the LPS from B. bronchiseptica and B.
parapertussishu is required for both survival in naive serum and
virulence in SCID mice (17; V. C. Burns and E. T. Harvill,
unpublished results). The wbm genes are required for assembly
of O-antigen structures in B. bronchiseptica and B. parapertus-
sishu, but these genes are not present in B. pertussis, which does
not survive in naive serum and is avirulent in SCID mice (Fig.
3). Although B. parapertussisov has the wbm genes and is resis-
tant to naive serum, it is avirulent in SCID mice, suggesting
that it lacks some other factor required for virulence. To-
gether, these results suggest that the different LPS structures
on these closely related bordetellae influence their differing
levels of resistance in serum and virulence in immunocompe-
tent and immunodeficient mice.
Macrophage cytotoxicity. Previous studies (15, 17, 37) found
B. bronchiseptica, but not B. pertussis, to be cytotoxic to the
mouse macrophage-like cell line J774. Therefore, the cytotox-
icity of the 12822 strain of B. parapertussishu was compared
with that of other bordetellae (Fig. 5). Like both B. pertussis
strains tested (Tohama I and GMT1), strain 12822 was mini-
mally cytotoxic to J774 cells, whereas the RB50 strain of B.
bronchiseptica and the Fr107 strain of B. parapertussisov were
highly cytotoxic. The Bvg-phase-locked derivative of RB50,
strain RB53, was highly cytotoxic, whereas the Bvg-phase-
locked derivative of RB50, strain RB54, was minimally cyto-
toxic, indicating that cytotoxicity is regulated by BvgAS, as
previously shown (15). The WD3 derivative of RB50 contains
an in-frame deletion mutation of bscN (bscN), which is a
putative ATPase required by the type III secretion (TTS) sys-
tem for protein export (37). Cytotoxicity of WD3 was about
25% (P  0.001) of that of RB50, RB53, and FR107 but still
greater (P  0.03) than that of both strains of B. pertussis
tested, RB54 and 12822.
All bordetellae studied in this investigation have genes en-
coding a TTS system, but expression has only been detected in
B. bronchiseptica and B. parapertussisov (37). As previously
shown (37, 39), the cytotoxicity of B. bronchiseptica to the
FIG. 3. Serum antimicrobial resistance of the RB50 strain of B.
bronchiseptica, the FR107 strain of B. parapertussisov, the 12822 strain
of B. parapertussishu, and the Tohama I strain of B. pertussis. Bacteria
were grown to mid-log phase in SS broth and diluted in PBS so that a
total of 1,000 bacteria were incubated at 37°C for 1 h in 100 l of 90%
serum obtained from rabbits that were Bordetella free (naive) or im-
munized with heat-killed RB50, Fr107, 12822, or Tohama I. Bars
represent means  SE (n  3).
FIG. 4. Survival of SCID-beige mice inoculated with the 12822
strain of B. parapertussishu (filled square), the RB50 strain of B. bron-
chiseptica (filled circle), the FR107 strain of B. parapertussisov (filled
triangle), or the Tohama I (filled diamond) or GMT1 (open square)
strains of B. pertussis. Groups of four mice were inoculated intranasally
with a high dose (50 l of PBS containing 5  104 CFU) of the
indicated strains.
3782 HEININGER ET AL. INFECT. IMMUN.
macrophage-like cell line J774 is much reduced by deletion of
bscN or deletion of bvgAS, which is required for expression of
bscN. Interestingly, the relative differences in infection pattern,
virulence, and serum antimicrobial resistance observed among
the classical bordetellae tested in this investigation did not
correlate with their observed cytotoxicity in vitro. Cytotoxicity
did, however, correlate with the previously observed expres-
sion of a functional TTS system in B. bronchiseptica and tran-
scription of bscN in B. parapertussisov, suggesting that TTS is
involved in cytotoxicity. In comparison, transcription of TTS
genes was not detected (37) in B. parapertussishu or the strains
of B. pertussis tested in this investigation, and these strains, like
the TTS mutant of B. bronchiseptica, are not cytotoxic.
This investigation prompts speculation on the evolution of
host range (see also reference 12). The ability of B. paraper-
tussishu to establish infections in mice that are comparable to
those by B. bronchiseptica suggests that this bacterium has not
lost the ability to infect nonhuman animals. Their clinical iso-
lation exclusively from humans could reflect sampling and
identification biases, i.e., B. parapertussishu, may routinely in-
fect animals in which respiratory infections are not monitored
or from which bordetellae are not identifiable by standard
methods. Alternatively, B. parapertussishu may in fact be lim-
ited in host range to humans, but this limitation may result
from constraints due to transmissibility or host availability
rather than to its absolute ability to colonize the respiratory
tracts of nonhuman hosts. As sequences for the Bordetella
genomes become available, comparative genome-based ap-
proaches, such as DNA microarrays, will reveal those bacterial
(12) and host genes differentially expressed among the borde-
tellae during an infection. Testing of these genes by the assays
described here is an approach for relating individual genes to
species-specific Bordetella phenotypes that will lead to a better
understanding of the evolution of host range and the molecular
basis of Bordetella pathogenesis.
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